Literature DB >> 21199185

Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study.

F Valldeoriola1, C Coronell, C Pont, M T Buongiorno, A Cámara, C Gaig, Y Compta.   

Abstract

BACKGROUND: Symptoms of Parkinson's disease (PD) are usually controlled by a continuous titration of medication and addition of multiple therapies over the course of the disease. Therapeutic complex schemes, polymedication, comorbidities and the number of medications required contribute to non-adherence.
METHODS: This cross-sectional survey was performed in 418 patients with PD on treatment with any antiparkinsonian medication. Patient adherence was assessed through physicians' subjective perception and the Morisky-Green test (MGT). Several social, demographic and clinical features were correlated through bivariate and multivariate analyses.
RESULTS: According to the physician's opinion 93.7%, and according to the MGT 60.4% of patients were adherent to parkinsonian therapy. The bivariate analysis showed greater adherence in patients with a high level of knowledge about the disease (62.8%), good clinical control (63.6%), a spouse or life partner (63%) and higher incomes (66%). Negative correlation with psychiatric symptoms was found. In relation to the MGT, the logistic regression model showed a negative correlation between cognitive deterioration and psychiatric pathology and adherence to therapy.
CONCLUSIONS: The physician's impression overestimated the compliance of patients when compared with an objective evaluation such as the MGT. Cognitive impairment and psychiatric symptoms are the clinical variables associated with a lower level of adherence.
© 2010 The Author(s). European Journal of Neurology © 2010 EFNS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21199185     DOI: 10.1111/j.1468-1331.2010.03320.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  29 in total

Review 1.  Medication nonadherence in Parkinson's disease.

Authors:  Jori E Fleisher; Matthew B Stern
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

2.  Psychosocial risk factors, pre-motor symptoms and first-time hospitalization with Parkinson's disease: a prospective cohort study.

Authors:  A J Clark; B Ritz; E Prescott; N H Rod
Journal:  Eur J Neurol       Date:  2013-02-23       Impact factor: 6.089

Review 3.  Early versus delayed initiation of pharmacotherapy in Parkinson's disease.

Authors:  Matthias Löhle; Carl-Johan Ramberg; Heinz Reichmann; Anthony H V Schapira
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

4.  Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.

Authors:  Nadia Harbeck; Maria Blettner; Peyman Hadji; Christian Jackisch; Hans-Joachim Lück; Christine Windemuth-Kieselbach; Silke Zaun; Renate Haidinger; Doris Schmitt; Hilde Schulte; Ulrike Nitz; Rolf Kreienberg
Journal:  Breast Care (Basel)       Date:  2013-05       Impact factor: 2.860

Review 5.  Medication adherence in patients with Parkinson's disease.

Authors:  Naveed Malek; Donald G Grosset
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

6.  Prospective memory deficits are associated with poorer everyday functioning in Parkinson's disease.

Authors:  Eva Pirogovsky; Steven Paul Woods; J Vincent Filoteo; Paul E Gilbert
Journal:  J Int Neuropsychol Soc       Date:  2012-07-30       Impact factor: 2.892

7.  Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx).

Authors:  Jori E Fleisher; Nabila A Dahodwala; Sharon X Xie; Mark Mayo; Daniel Weintraub; Joshua Chodosh; Judy A Shea
Journal:  J Parkinsons Dis       Date:  2016-04-02       Impact factor: 5.568

8.  Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items".

Authors:  G Fabbrini; G Abbruzzese; P Barone; A Antonini; M Tinazzi; G Castegnaro; S Rizzoli; D E Morisky; P Lessi; R Ceravolo
Journal:  Neurol Sci       Date:  2013-06-01       Impact factor: 3.307

9.  Self-compassion and reactions to serious illness: the case of HIV.

Authors:  John M Brion; Mark R Leary; Anya S Drabkin
Journal:  J Health Psychol       Date:  2013-01-08

10.  No Difference on Adherence Between Immediate-Release Versus Extended-Release Dopamine Agonists in Uninsured Subjects with Parkinson's Disease.

Authors:  Lisette Bazán-Rodríguez; Amin Cervantes-Arriaga; Rodrigo Llorens-Arenas; Humberto Calderón-Fajardo; Mayela Rodríguez-Violante
Journal:  Mov Disord Clin Pract       Date:  2015-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.